[{"orgOrder":0,"company":"AstralBio","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"IBIO-600","moa":"MSTN","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"AstralBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AstralBio \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"AstralBio \/ iBio"}]

Find Clinical Drug Pipeline Developments & Deals by AstralBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : Under the licensing agreement, iBio will be solely responsible for the research and development, manufacturing and commercialization of IBIO-600 for obesity and cardiometabolic treatment.

                          Product Name : IBIO-600

                          Product Type : Antibody

                          Upfront Cash : $0.7 million

                          January 03, 2025

                          Lead Product(s) : IBIO-600

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : iBio

                          Deal Size : $28.7 million

                          Deal Type : Licensing Agreement

                          blank